Skip to main content
Fig. 3 | BMC Pharmacology and Toxicology

Fig. 3

From: Dihydroisotanshinone I combined with radiation inhibits the migration ability of prostate cancer cells through DNA damage and CCL2 pathway

Fig. 3

Effects of DT on the protein secretion of IL8 or CCL2 from prostate cancer cells and on human normal fibroblasts migration in the THP1 cell medium. The condition medium of coculture with DU145 cell or PC-3 cells were collected from untreated cells, cells treated with DMSO or indicated treatment for 24 h. The secretion of human IL8 was measured with ELISA kits (a, c). The secretion of human CCL2 was measured with ELISA kits (b, d). e The migration ability of IMR-90 cells were measured with the transwell migration assay. After treated with indicated drugs for 24 h, the photographs (× 100) were taken and the migratory cells were measured using AlphaEase®FC StandAlone Software. Numbers of the migratory IMR-90 cells in each group were normalized to the control. f The migration ability of human prostate cancers in the macrophages medium were measured by the transwell migration assay. THP1 cells were treated with DMSO or DT for 24 h. Then the conditioned medium was collected and placed in the lower chamber. In the group of DT+ 5 pg/mL CCL2, 5 pg/mL CCL2 was added into the condition medium of this group. Then, PC-3 cells were then placed on the upper chamber for the migration assay. After incubation for 24 h, the photographs (× 100) were taken and the migratory cells were measured using AlphaEase®FC StandAlone Software. The quantification of the indicated migratory cells numbers in each group were normalized to the control. All the results are representative of at least three independent experiments. (Error bars = mean ± S.E.M. Asterisks (*) mark samples significantly different from blank group with p < 0.05)

Back to article page